妇科手术患者蛛网膜下腔注射布比卡因与左旋布比卡因运动阻滞效应的比较

目的 比较妇科手术患者蛛网膜下腔注射布比卡因与左旋布比卡因运动阻滞的的效应.方法 拟在脊椎-硬膜外联合麻醉下行妇科手术的患者60例,ASA Ⅰ或Ⅱ级,年龄20～60岁,身高155～170 cm,体重指数<30 kg/m2,随机分为2组(n=30),布比卡因组(B组):蛛网膜下腔注射等比重0.5%布比卡因;左旋布比卡因组(L组):蛛网膜下腔注射等比重0.5%左旋布比卡因.采用序贯法进行试验,每组第1例患者局麻药剂量均为5 mg,剂量变化梯度为1 mg.运动阻滞有效定义为蛛网膜下腔注药结束后20 min内双下肢改良Bromage评分均达到3分.若上1例有效,则下1例采用低一级剂量;若无效,则下1例采用高一级剂量.采用概率单位回归法计算两药运动阻滞的半数有效剂量(ED50)及其95%可信区间(95%CI).结果 布比卡因运动阻滞的ED50及其95%CI为6.04(5.30～6.93)mg,左旋布比卡因运动阻滞的ED50及其95%CI为9.55(8.62～10.97)mg,布比卡因运动阻滞的ED50低于左旋布比卡因(P<0.01);左旋布比卡因与布比卡因运动阻滞的效价比及其95%CI为0.63(0.52～0.75).结论 左旋布比卡因蛛网膜下腔麻醉时运动阻滞的效应低于布比卡因.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

左旋布比卡因蛛网膜下腔阻滞的进展

左旋布比卡因是一种新型的长效酰胺类局麻药,为麻醉中常用局麻药物布比卡因的左旋体.左旋布比卡因中枢神经系统和心脏毒性明显低于布比卡因,且具有儿乎与布比卡因相同的麻醉效能.长效局麻药用于蛛网膜下腔的安全性长期以来一直是麻醉学家关注的问题,近年来国内外已有很多学者对左旋布比卡因蛛网膜下腔的应用进行了大量研究.现就左旋布比卡因蛛网膜下腔阴滞的安全性、可行性和临床应用等方面的进展作一综述.     

蛛网膜下腔注射罗哌卡因与布比卡因运动神经阻滞效力的比较

Objective To determine the median effective doae (ED50) for motor block after intrathecal ropivacaine and bupivacaine. Methods Sixty ASA Ⅰ or Ⅱ patients, aged 18-64, weighing 46-75 kg, undergoing elective urological surgery under combined spinal-epidural anesthesia, were randomized into 2 groups ( n = 30each) receiving intrathecal 0.5% ropivacaine and 0.5% bupivacaine respectively. The ED50 was determined by up-down sequential allocation. The initial dose was 4 mg. Each time the dose increased/decreased by 1 mg. Efficacy was determined by the occurrence of any motor block in either lower extremity (modified Bromage scale > 0)within 5 or 10 min after the spinal injection. Results The intrathecal ED50 for motor block was 6.68 mg for ropivacaine (95% confidence interval 6.27-7.13 mg) and 4.07 mg for bupivacaine (95% confidence interval 3.56-4.47mg) . The relative motor blocking potency ratio was ropivacaine/bupivacaine 0.61. Conclusion The potency of intrathecal ropivacaine is lower than that of bupivacaine for motor block.     

蛛网膜下腔注射罗哌卡因与布比卡因运动神经阻滞效力的比较

Objective To determine the median effective doae (ED50) for motor block after intrathecal ropivacaine and bupivacaine. Methods Sixty ASA Ⅰ or Ⅱ patients, aged 18-64, weighing 46-75 kg, undergoing elective urological surgery under combined spinal-epidural anesthesia, were randomized into 2 groups ( n = 30each) receiving intrathecal 0.5% ropivacaine and 0.5% bupivacaine respectively. The ED50 was determined by up-down sequential allocation. The initial dose was 4 mg. Each time the dose increased/decreased by 1 mg. Efficacy was determined by the occurrence of any motor block in either lower extremity (modified Bromage scale > 0)within 5 or 10 min after the spinal injection. Results The intrathecal ED50 for motor block was 6.68 mg for ropivacaine (95% confidence interval 6.27-7.13 mg) and 4.07 mg for bupivacaine (95% confidence interval 3.56-4.47mg) . The relative motor blocking potency ratio was ropivacaine/bupivacaine 0.61. Conclusion The potency of intrathecal ropivacaine is lower than that of bupivacaine for motor block.     

蛛网膜下腔注射罗哌卡因与布比卡因运动神经阻滞效力的比较

目的 比较蛛网膜下腔注射罗哌卡因与布比卡因的运动神经阻滞效力.方法 择期脊椎.硬膜外麻醉下拟行泌尿外科腔镜手术患者60例,年龄18～64岁,体重46～75 kg,ASA分级Ⅰ或Ⅱ级,采用随机数字表法,将患者随机分为2组(n=30):0.5%罗哌卡因组和0.5%布比卡因组.按照序贯法进行试验,阻滞有效,下一例患者采用低一级剂量,阻滞无效,下一例患者采用高一级剂量,初始剂量均为4 mg,剂量梯度1 mg,阻滞有效的标准:蛛网膜下腔给药后5或10 min时任一下肢的任一种运动神经阻滞评分>0分.采用序贯法计算蛛网膜下腔注射罗哌卡因或布比卡因运动神经阻滞的半数有效剂量(ED50)及其95%置信区间.结果 患者蛛网膜下腔注射罗哌卡因和布比卡因运动神经阻滞的ED50及其95%置信区间分别为6.68(6.27～7.13)mg和4.07(3.56～4.47)mg,效力比为O.61.结论 患者蛛网膜下腔注射罗哌卡因运动神经阻滞效力低于布比卡因.

Abstract：

Objective To determine the median effective doae (ED50) for motor block after intrathecal ropivacaine and bupivacaine. Methods Sixty ASA Ⅰ or Ⅱ patients, aged 18-64, weighing 46-75 kg, undergoing elective urological surgery under combined spinal-epidural anesthesia, were randomized into 2 groups ( n = 30each) receiving intrathecal 0.5% ropivacaine and 0.5% bupivacaine respectively. The ED50 was determined by up-down sequential allocation. The initial dose was 4 mg. Each time the dose increased/decreased by 1 mg. Efficacy was determined by the occurrence of any motor block in either lower extremity (modified Bromage scale > 0)within 5 or 10 min after the spinal injection. Results The intrathecal ED50 for motor block was 6.68 mg for ropivacaine (95% confidence interval 6.27-7.13 mg) and 4.07 mg for bupivacaine (95% confidence interval 3.56-4.47mg) . The relative motor blocking potency ratio was ropivacaine/bupivacaine 0.61. Conclusion The potency of intrathecal ropivacaine is lower than that of bupivacaine for motor block.     

The relative motor blocking potencies of bupivacaine and levobupivacaine in labor

Minimum local analgesic concentrations (MLAC) have been used to determine the epidural analgesic potencies of bupivacaine and its levo- counterpart. There are no reports of the motor blocking potencies of these drugs. In this study we sought to determine the motor block MLAC of both drugs and determine the relative potency ratio. Sixty ASA physical status I-II parturients were randomized. The first woman in each group received 0.25% wt/vol. Up-down sequential allocation was used to determine subsequent concentrations at a testing interval of 0.025% wt/vol. Effective motor block was defined as a Bromage score <4 within 30 min. The up-down sequences were analyzed with the Dixon and Massey method and probit regression. Two-sided P < 0.05 defined significance. The motor block MLAC for bupivacaine was 0.27% wt/vol (95% confidence interval [CI], 0.25-0.30) and for levobupivacaine was 0.31% wt/vol (95% CI, 0.29-0.34) (P = 0.024), with a levobupivacaine/bupivacaine potency ratio of 0.87 (95% CI, 0.77-0.98). This is the first study to estimate the motor-blocking potency ratio of bupivacaine and levobupivacaine in labor. This study demonstrates that the S-enantiomer of bupivacaine is less potent at motor block than the racemate. IMPLICATIONS: We estimated the motor-blocking potency ratio of bupivacaine and levobupivacaine in labor and demonstrated that the S-enantiomer of bupivacaine is less potent at motor block than the racemate.     

妇科硬膜外左旋与消旋布比卡因运动阻滞效能比较

硬膜外长效酰胺类局麻药具有感觉与运动阻滞分离的特点,高浓度局麻药产生较好肌肉松弛,利于手术;较低浓度则镇痛效果良好而无运动阻滞,则利于术后或分娩镇痛等临床需要。本研究拟通过序贯法测定妇科手术中硬膜外左旋布比卡因(LBUP)与消旋布比卡因(BUP)运动阻滞最低有效浓度(MML     

三种不同局麻药腰麻最大运动阻滞效应的比较

目的 采用序贯试验评估罗哌卡因、左旋布比卡因和布比卡因鞘内注射后达到Bromage 3级的半数有效剂量(ED50),比较三种局麻药腰麻的运动阻滞效应.方法 腰-硬联合麻醉(CSEA)下择期行妇科手术患者99例,随机分为罗哌卡因组、左旋布比卡因组和布比卡因组,分别鞘内注射0.5%等比重罗哌卡因、左旋布比卡因或布比卡因,起始剂量均为7 mg,剂量变化梯度为1mg,鞘内注药后25 min内双下肢改良Bromage达到3级为有效.结果 罗哌卡因组腰麻产生最大运动阻滞的ED50 为9.62 mg,95%可信区间(CI)为9.16～10.09 mg;左旋布比卡因组的ED50为9.55mg,95% CI为9.01～10.11 mg;布比卡因组的ED50为6.08 mg,95% CI为5.39～6.80 mg.罗哌卡因最大运动阻滞相对效价比是布比卡因的0.63倍(95% CI 0.56～O.73).结论 罗哌卡因和左旋布比卡因腰麻的运动阻滞效应明显低于布比卡因,而罗哌卡因与左旋布比卡因无明显差异.     

The effects of intrathecal levobupivacaine and bupivacaine in the elderly

The objective of this study was to compare the block durations and haemodynamic effects associated with intrathecal levobupivacaine or bupivacaine in elderly patients undergoing transurethral prostate surgery. Eighty patients were prospectively randomised to receive plain 1.5 ml levobupivacaine 0.5% (group levobupivacaine) or 1.5 ml plain bupivacaine 0.5% (group bupivacaine) in combination with fentanyl 0.3 ml (15 μg) for spinal anaesthesia. The time to reach T10 and peak sensory block level, and to maximum motor block were significantly shorter in group bupivacaine compared to group levobupivacaine (p < 0.05). Peak sensory block level was also significantly higher in group bupivacaine. In group bupivacaine, mean arterial pressure was significantly lower than group levobupivacaine, starting from 10 min until 30 min after injection (p < 0.05). Hypotension and nausea were less common in group levobupivacaine than group bupivacaine (p < 0.05). Because of the better haemodynamic stability and fewer side-effects associated with levobupivacaine, it may be preferred for spinal anaesthesia in elderly patients.